GSRGT 2020: Management of Chemotherapy Resistant Germ Cell Tumors in 2020
GSRGT 2020: Management of Chemotherapy Resistant Germ Cell Tumors in 2020 - Keynote Commentary (Urotoday.com) To provide a context to the keynote lecture by Dr. Andrea Necchi discussing the management of chemotherapy-resistant germ cell tumors at the inaugural Global Society of Rare Genitourinary Tumors virtual summit, Dr. Lucia Nappi provided a commentary discussion of this topic. By way of background, Dr. Nappi notes that 20-30% of patients will relapse after first-line therapy, and the prognosis after second-line therapy is less favorable, with only 15-30% of patients maintaining a conti...
Source: urotoday.com